现代生物医药技术的迅猛发展正在改变着人们的生活。作为一种新的战略管理模式,战略联盟已逐步成为推进生物医药技术产业转化的重要手段。西方主要发达国家在产学研的优势互补模式和结合机制等方面都取得了显著的效果,并极大地推动了生物技术产业的快速发展。近年来,中国开始重视战略联盟的发展模式,然而在生物医药领域中国的技术创新战略联盟依然处于起步阶段,有关的机制和体制尚需健全。本文首先介绍了发达国家发展战略联盟的先进经验,并通过剖析美国的成功模式对当前中国生物医药产业技术创新战略联盟的现状和不足进行解读,提出发展思路与对策。
Biotechnology is a rapidly expanding field of science and technology to change our life. It has been realized that strategic alliance is an important mode for technology transfer from biomedical research to the industry. Appropriate mechanisms of Industry-Academe-Research Institute strategic alliance have been built in major developed countries, significantly propelling the growth of biotechnology industry. Such advanced cooperation mode has been recently gained increasing concerns by China government. However, strategic alliance in China is in its preliminary stage with very small scale and inadequate functionality, its expected benefits are still far from significant. In this paper, we first review the development and management of effective strategic alliances in some leading countries; we then examine the successful mode of strategic alliances that is performing in USA, and identify the difficulties of China’s strategic alliance development based on its current progress. The future development of biomedical strategic alliances in China is discussed.
邓宁,敖翼,关镇和,苏月.中国生物医药产业技术创新战略联盟发展思路与对策[J].生物化学与生物物理进展,2012,39(7):631-639
复制生物化学与生物物理进展 ® 2024 版权所有 ICP:京ICP备05023138号-1 京公网安备 11010502031771号